Your browser doesn't support javascript.
Hematopoietic stem cells from SARS-CoV-2 infected donors. Is there a risk for transmission?
Transfusion Medicine and Hemotherapy ; 49(Supplement 1):76, 2022.
Article in English | EMBASE | ID: covidwho-2223871
ABSTRACT

Background:

Since the global COVID-19 pandemic, the supply of patients with hematopoietic stem cells is challenging. On day of collection, donor for PBSC is completely mobilized and the patient in complete aplasia. In this situation, a cancellation or deferral of collection has life-threating impact on the recipient. In this case series we investigated the feasibility and the outcome of donors, which were tested positive for SARS-CoV-2 around the day of collection. Method(s) Since the availability of SARS-CoV-2 antigen rapid test systems, all stem cell donors in our institution get tested on the day of collection before entering the facility. For bone marrow donors an additional SARS-CoV-2 PCR test is required. Furthermore, donors are instructed to perform ag-test in case of symptoms of an infection before and after collection. In case of a positive test result before collection, donor registry, donor centre and at least the donor was consulted how to proceed. For bone marrow harvest, the collection was cancelled. Result(s) Between November 2021 and April 2022 we performed 571 PBSC-donations and 54 bone marrow harvests. Of them, five donors were enrolled into this observational trial, 4 PBSCs and 1 bone marrow harvest who was tested positive after the donation. In all cases, we collected sufficient amounts of stem cells for transplantation. Donor 2 developed circulation problems and fever during donation, donor 4 after the donation. All symptoms resolved after a short period. All products have been administered to the patient, up to date there are no reports concerning transmission of SARS-CoV-2 so far (Table 1). Conclusion(s) SARS-CoV-2 is detectable in blood stream of hospitalized patients but little is known about viremia in immunocompetent donors. Transmission via transfusions has not been described, yet, but the impact of G-CSF during infection and the cellularity of the source opens up questions concerning the safety of stem cell products. In our case series, we observed no serious side effects, neither from donation or infection. Clinically, there was no transmission reported after administration. (Table Presented).
Keywords

Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Prognostic study Language: English Journal: Transfusion Medicine and Hemotherapy Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Prognostic study Language: English Journal: Transfusion Medicine and Hemotherapy Year: 2022 Document Type: Article